BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hürlimann S, Kullak-Ublick GA. Rivaroxaban postmarketing risk of liver injury. J Hepatol 2014;61:293-300. [PMID: 24681117 DOI: 10.1016/j.jhep.2014.03.026] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Miller JB, Caldwell SH. Use of Newer Anticoagulants in Patients with Cirrhosis. Curr Hepatology Rep 2022. [DOI: 10.1007/s11901-022-00585-1] [Reference Citation Analysis]
2 Islam R, Kundu S, Jha SB, Rivera AP, Flores Monar GV, Islam H, Puttagunta SM, Sange I. Cirrhosis and Coagulopathy: Mechanisms of Hemostasis Changes in Liver Failure and Their Management. Cureus. [DOI: 10.7759/cureus.23785] [Reference Citation Analysis]
3 Su F, Northup PG. Anticoagulants and Antiplatelet Agents in Cirrhosis. Pharmacotherapy for Liver Cirrhosis and Its Complications 2022. [DOI: 10.1007/978-981-19-2615-0_3] [Reference Citation Analysis]
4 Teschke R, Danan G. Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis. Medicines (Basel) 2020;7:E62. [PMID: 33003400 DOI: 10.3390/medicines7100062] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 11.7] [Reference Citation Analysis]
5 Björnsson HK, Gudmundsson DO, Björnsson ES. Liver injury caused by oral anticoagulants: A population-based retrospective cohort study. Liver Int 2020;40:1895-900. [PMID: 32511827 DOI: 10.1111/liv.14559] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
6 Verheyen E, Kileci JA, Mathew JP. Single-Dose Rivaroxaban-Induced Acute Liver Injury. Am J Ther 2019;26:e538-40. [PMID: 29889676 DOI: 10.1097/MJT.0000000000000799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Danan G, Teschke R. Roussel Uclaf Causality Assessment Method for Drug-Induced Liver Injury: Present and Future. Front Pharmacol. 2019;10:853. [PMID: 31417407 DOI: 10.3389/fphar.2019.00853] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 11.8] [Reference Citation Analysis]
8 Teschke R. Idiosyncratic DILI: Analysis of 46,266 Cases Assessed for Causality by RUCAM and Published From 2014 to Early 2019. Front Pharmacol 2019;10:730. [PMID: 31396080 DOI: 10.3389/fphar.2019.00730] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 9.0] [Reference Citation Analysis]
9 Steuber TD, Howard ML, Nisly SA. Direct Oral Anticoagulants in Chronic Liver Disease. Ann Pharmacother 2019;53:1042-9. [PMID: 30947523 DOI: 10.1177/1060028019841582] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
10 Shavadia JS, Sharma A, Gu X, Neaton J, Deleve L, Holmes D, Home P, Eckel RH, Watkins PB, Granger CB. Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program. Clinical Trials 2019;16:253-62. [DOI: 10.1177/1740774519836766] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
11 Krishnan P, Ramadas P, Gangireddy R. Rivaroxaban Associated Cholestatic Jaundice. American Journal of Therapeutics 2018;25:e500-1. [DOI: 10.1097/mjt.0000000000000588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
12 Hanafy AS, Abd-Elsalam S, Dawoud MM. Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis. Vascul Pharmacol. 2018;. [PMID: 29886103 DOI: 10.1016/j.vph.2018.05.002] [Cited by in Crossref: 89] [Cited by in F6Publishing: 96] [Article Influence: 17.8] [Reference Citation Analysis]
13 Makam RCP, Hoaglin DC, McManus DD, Wang V, Gore JM, Spencer FA, Pradhan R, Tran H, Yu H, Goldberg RJ. Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis. PLoS One 2018;13:e0197583. [PMID: 29795629 DOI: 10.1371/journal.pone.0197583] [Cited by in Crossref: 42] [Cited by in F6Publishing: 46] [Article Influence: 8.4] [Reference Citation Analysis]
14 Peverelle M, Asadi K, Sinclair M. Drug-induced liver failure due to rivaroxaban. Ann Hematol 2018;97:2267-8. [DOI: 10.1007/s00277-018-3364-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
15 Licata A, Puccia F, Lombardo V, Serruto A, Minissale MG, Morreale I, Giannitrapani L, Soresi M, Montalto G, Almasio PL. Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases. Eur J Gastroenterol Hepatol 2018;30:226-32. [PMID: 29120909 DOI: 10.1097/MEG.0000000000001030] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
16 Teschke R, Danan G. Causality Assessment Methods in Drug-Induced Liver Injury. Methods in Pharmacology and Toxicology 2018. [DOI: 10.1007/978-1-4939-7677-5_27] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
17 Christopoulou EC, Filippatos TD, Elisaf MS. Non-hemorrhage-related adverse effects of rivaroxaban. Arch Med Sci Atheroscler Dis 2017;2:e108-12. [PMID: 29379891 DOI: 10.5114/amsad.2017.72533] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
18 De Gottardi A, Trebicka J, Klinger C, Plessier A, Seijo S, Terziroli B, Magenta L, Semela D, Buscarini E, Langlet P, Görtzen J, Puente A, Müllhaupt B, Navascuès C, Nery F, Deltenre P, Turon F, Engelmann C, Arya R, Caca K, Peck-Radosavljevic M, Leebeek FWG, Valla D, Garcia-Pagan JC; VALDIG Investigators. Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. Liver Int 2017;37:694-9. [PMID: 27778440 DOI: 10.1111/liv.13285] [Cited by in Crossref: 141] [Cited by in F6Publishing: 147] [Article Influence: 23.5] [Reference Citation Analysis]
19 Wang XX, Fang XX. Impact of coagulation function and anticoagulation therapy on liver fibrosis. Shijie Huaren Xiaohua Zazhi 2017; 25(10): 897-903 [DOI: 10.11569/wcjd.v25.i10.897] [Reference Citation Analysis]
20 Potpara TS, Lip GY. Drug-induced liver injury with oral anticoagulants: a threat or not? Heart 2017;103:809-11. [DOI: 10.1136/heartjnl-2016-310983] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
21 Bunchorntavakul C, Reddy KR. Drug Hepatotoxicity: Newer Agents. Clin Liver Dis 2017;21:115-34. [PMID: 27842767 DOI: 10.1016/j.cld.2016.08.009] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 8.3] [Reference Citation Analysis]
22 Glenn K, Chen P, Musleh M, Pallivi R, Grilliot M. A Rare Case of Rivaroxaban Causing Delayed Symptomatic Hepatocellular Injury and Hyperbilirubinemia. Case Rep Gastrointest Med 2017;2017:5678187. [PMID: 28250999 DOI: 10.1155/2017/5678187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
23 Raschi E, De Ponti F. Drug-induced liver injury: Towards early prediction and risk stratification. World J Hepatol 2017;9:30-7. [PMID: 28105256 DOI: 10.4254/wjh.v9.i1.30] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
24 Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, Caldwell SH. Direct Oral Anticoagulants in Cirrhosis Patients Pose Similar Risks of Bleeding When Compared to Traditional Anticoagulation. Dig Dis Sci 2016;61:1721-1727. [DOI: 10.1007/s10620-015-4012-2] [Cited by in Crossref: 170] [Cited by in F6Publishing: 152] [Article Influence: 24.3] [Reference Citation Analysis]
25 Liew A, Douketis J. Portal vein thrombosis in patients with cirrhosis: underdiagnosis and undertreatment? Intern Emerg Med 2016;11:1037-40. [PMID: 27216797 DOI: 10.1007/s11739-016-1463-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Sarges P, Steinberg JM, Lewis JH. Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature. Drug Saf 2016;39:801-21. [DOI: 10.1007/s40264-016-0427-8] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 7.9] [Reference Citation Analysis]
27 Liakoni E, Rätz Bravo AE, Krähenbühl S. Hepatotoxicity of New Oral Anticoagulants (NOACs). Drug Saf. 2015;38:711-720. [PMID: 26138527 DOI: 10.1007/s40264-015-0317-5] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 6.3] [Reference Citation Analysis]
28 Anastasia EJ, Rosenstein RS, Bergsman JA, Parra D. Use of apixaban after development of suspected rivaroxaban-induced hepatic steatosis; a case report. Blood Coagul Fibrinolysis 2015;26:699-702. [PMID: 26154612 DOI: 10.1097/MBC.0000000000000363] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
29 Intagliata NM, Maitland H, Caldwell SH. Direct Oral Anticoagulants in Cirrhosis. Curr Treat Options Gastroenterol. 2016;14:247-256. [PMID: 27020266 DOI: 10.1007/s11938-016-0092-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
30 Adis Medical Writers. Beware of hepatotoxicity risk with new oral anticoagulants (NOACs). Drugs Ther Perspect 2016;32:113-118. [DOI: 10.1007/s40267-015-0274-1] [Reference Citation Analysis]
31 Finazzi G, Ageno W. Direct oral anticoagulants in rare venous thrombosis. Intern Emerg Med 2016;11:167-70. [PMID: 26875179 DOI: 10.1007/s11739-016-1398-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
32 Danan G, Teschke R. RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci. 2015;17:14. [PMID: 26712744 DOI: 10.3390/ijms17010014] [Cited by in Crossref: 355] [Cited by in F6Publishing: 371] [Article Influence: 44.4] [Reference Citation Analysis]
33 Baig M, Wool KJ, Halanych JH, Sarmad RA. Acute Liver Failure after Initiation of Rivaroxaban: A Case Report and Review of the Literature. N Am J Med Sci 2015;7:407-10. [PMID: 26605205 DOI: 10.4103/1947-2714.166221] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
34 Cordeanu M, Lambert A, Gaertner S, Nouri S, Mirea C, Alt-Tebacher M, Stephan D. Apixaban-induced hepatotoxicity. Int J Cardiol 2016;204:4-5. [PMID: 26649445 DOI: 10.1016/j.ijcard.2015.11.147] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
35 Hahn KJ, Morales SJ, Lewis JH. Enoxaparin-Induced Liver Injury: Case Report and Review of the Literature and FDA Adverse Event Reporting System (FAERS). Drug Saf Case Rep 2015;2:17. [PMID: 27747729 DOI: 10.1007/s40800-015-0018-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
36 Spiller HA, Mowry JB, Aleguas A, Griffith JR, Goetz R, Ryan ML, Bangh S, Klein-Schwartz W, Schaeffer S, Casavant MJ. An Observational Study of the Factor Xa Inhibitors Rivaroxaban and Apixaban as Reported to Eight Poison Centers. Ann Emerg Med. 2016;67:189-195. [PMID: 26298448 DOI: 10.1016/j.annemergmed.2015.07.014] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
37 Raschi E, De Ponti F. Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk. World J Hepatol 2015;7:1761-71. [PMID: 26167249 DOI: 10.4254/wjh.v7.i13.1761] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.8] [Reference Citation Analysis]
38 Stöllberger C, Bastovansky A, Finsterer J. Fatal intracerebral bleeding under rivaroxaban. Int J Cardiol 2015;201:110-2. [PMID: 26296048 DOI: 10.1016/j.ijcard.2015.06.081] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
39 Simonetto DA, Wysokinski WE, Kamath PS. Use of nontraditional anticoagulants in portal vein thrombosis: a note of caution. Hepatology 2015;61:2119. [PMID: 25266497 DOI: 10.1002/hep.27541] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
40 Martinez M, Tandra A, Vuppalanchi R. Reply: To PMID 24395623. Hepatology 2015;61:2119-20. [PMID: 25266638 DOI: 10.1002/hep.27542] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Barrett P, Vuppalanchi R, Masuoka H, Chalasani N. Severe drug-induced skin and liver injury from rivaroxaban. Dig Dis Sci 2015;60:1856-8. [PMID: 25559757 DOI: 10.1007/s10620-014-3504-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
42 Raschi E, Poluzzi E, Koci A, Salvo F, Pariente A, Biselli M, Moretti U, Moore N, De Ponti F. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol. 2015;80:285-293. [PMID: 25689417 DOI: 10.1111/bcp.12611] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 6.8] [Reference Citation Analysis]
43 Lambert A, Cordeanu M, Gaertner S, Nouri S, Alt M, Stephan D. Rivaroxaban-induced liver injury: Results from a venous thromboembolism registry. Int J Cardiol 2015;191:265-6. [PMID: 25981364 DOI: 10.1016/j.ijcard.2015.04.248] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
44 Paracetamol/rivaroxaban. Reactions Weekly 2014;1521:133-133. [DOI: 10.1007/s40278-014-3938-z] [Reference Citation Analysis]
45 Moore N, Blin P, Gulmez SE. New oral anticoagulants (NOAC) and liver injury. J Hepatol 2014;61:198-9. [PMID: 24837361 DOI: 10.1016/j.jhep.2014.05.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]